Surabgene Lomparvovec(Surabgene Lomparvovec) - 药物靶点：VEGF_在研适应症：脉络膜新生血管，II型糖原贮积病，湿性年龄相关性黄斑变性_专利_临床

概要

基本信息

药物类型

DNA编码的单抗、腺相关病毒基因治疗

别名

Sura-vec、ABBV RGX 314、ABBV-RGX-314

+ [2]

靶点

VEGF

作用方式

抑制剂

作用机制

VEGF抑制剂(血管内皮生长因子抑制剂)

治疗领域

神经系统疾病遗传病与畸形内分泌与代谢疾病+ [3]

在研适应症

脉络膜新生血管II型糖原贮积病湿性年龄相关性黄斑变性+ [3]

非在研适应症-

原研机构

RegenxBio, Inc.

在研机构

AbbVie, Inc.

RegenxBio, Inc.

Clearside Biomedical, Inc.

非在研机构-

权益机构

RegenxBio, Inc.

Clearside Biomedical, Inc.

AbbVie, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 317694171

关联

10

项与 Surabgene Lomparvovec 相关的临床试验

NCT07007065

/ Recruiting临床3期

A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD).
Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD). Participants will be placed into 1 of 3 groups, called treatment arms. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis of previously treated nAMD will be enrolled. Around 561 participants will be enrolled in the study at approximately 150 sites worldwide.
Participants in groups 1 and 2 will receive a single subretinal dose of ABBV-RGX-314. Participants in group 3 will receive Ranibizumab as needed throughout the study. Ranibizumab will be given as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection), and ABBV-RGX-314 will be given as a subretinal (between the retina and the back of the eye) injection. The Assessment Period begins after randomization (1:1:1) to one of the ABBV-RGX-314 treatment groups or control at Week -2 and lasts up to 5 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2025-11-05

申办/合作机构

AbbVie, Inc.

NCT06942520

/ Recruiting临床2期

A Randomized, Open Label, Controlled, Phase 2 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 AAV Gene Therapy Administered Via Subretinal Delivery in Participants With Center Involved Diabetic Macular Edema

Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)

开始日期2025-03-18

申办/合作机构

Sierra Eye Associates

[+1]

NCT05407636

/ Recruiting临床3期

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. ABBV-RGX-314 is being developed as a potential one-time treatment for wet AMD.

开始日期2022-01-13

申办/合作机构

AbbVie, Inc.

[+1]

100 项与 Surabgene Lomparvovec 相关的临床结果

登录后查看更多信息

100 项与 Surabgene Lomparvovec 相关的转化医学

登录后查看更多信息

100 项与 Surabgene Lomparvovec 相关的专利（医药）

登录后查看更多信息

15

项与 Surabgene Lomparvovec 相关的文献（医药）

2025-10-03·Translational Vision Science & Technology

Computational Fluid Dynamics Modeling of Intravitreal Ranibizumab Bolus Versus Subretinal ABBV-RGX-314 Transgene Product in Human Eyes

Article

作者: Kazemi, Mohammad ; Tamhane, Mitalee ; Shen, Jie ; Park, Jenny

Purpose:

ABBV-RGX-314 is being developed for neovascular age-related macular degeneration (nAMD). Computational fluid dynamics (CFDs) modeling in the eye enables simulation of drug distribution incorporating geometry and substructures of the eye across species. Given the similarity between ranibizumab and ABBV-RGX-314 transgene product (TP), ranibizumab intraocular pharmacokinetic (PK) data from literature were used to simulate intraocular drug distribution of ABBV-RGX-314 TP. This investigation aims to use CFD modeling to estimate retinal TP level based on aqueous humor (AH) TP level following subretinal (SR) injection of ABBV-RGX-314 in patients with nAMD.

Methods:

Ocular distribution of ranibizumab following a single intravitreal (IVT) injection was modeled in both monkey and human eyes independently. Following model validation, ABBV-RGX-314 TP distribution in human eyes was simulated following retinal transduction of ABBV-RGX-314.

Results:

Iterative simulations were performed to achieve similar AH ABBV-RGX-314 TP levels in patients with nAMD from phase I/IIa Study RGX-314-001. The CFD simulation estimated corresponding retinal TP concentrations of 1.86 to 5.50 µg/g at steady-state, which was assumed to be reached by 28 days and falls within the range of the estimated retinal ranibizumab trough retinal ranibizumab concentration (Ctrough; 0.718-5.37 µg/g) following monthly and every other month (EOM) dosing of 0.5 mg ranibizumab in patients with nAMD.

Conclusions:

The current study results predict that the 2 pivotal trial ABBV-RGX-314 doses (6.4E10 and 1.3E11 genome copies/eye) are expected to achieve and maintain sufficient retinal ABBV-RGX-314 TP levels for the treatment of nAMD.

Translational Relevance:

CFD modeling effectively bridges limited human ocular PK data with rich preclinical data, supporting model-informed drug development (MIDD) for clinical dose selection.

2025-08-01·Graefe's Archive for Clinical and Experimental Ophthalmology

Gene therapy in neovascular age related macular degeneration: an update

Review

作者: Quesada, Erika ; Campos, Xiomara ; Rojas, Sofía ; Wu, Lihteh

Neovascular age-related macular degeneration (NV-AMD) is a leading cause of preventable blindness in the elderly. Intravitreal injections of anti-VEGF agents are currently the treatment of choice for NV-AMD. However this treatment is burdensome and fosters non-compliance which leads to inferior visual outcomes. Gene therapy has emerged as a promising therapeutic option for NV-AMD that may improve these outcomes. Potential risks of gene therapy include a potential immune response that may be elicited by the vector, accidental activation of oncogenes or inactivation of tumor suppresor genes leading to malignant transformation via insertational mutagenesis and integration of the viral DNA inserts into the host's DNA. The main strategy of current gene therapy for NV-AMD has focused on delivering transgenes that express anti-angiogenic proteins that directly or indirectly inhibit the VEGF pathway. Ixoberogene soroparvovec, RGX-314 and 4D-150 are the leading NV-AMD genetic treatment programs. Pre-clinical models suggest that genome surgery with clustered regularly interspaced short palindromic repeats (CRISPR) may be another option in the future.

2025-01-01·EYE

Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues

Review

作者: Shirian, Jonathan D ; Shirian, Jonathan D. ; Shukla, Priya ; Singh, Rishi P. ; Singh, Rishi P

Abstract:

Neovascular age-related macular degeneration (nAMD) can lead to significant vision impairment through the growth of abnormal neovascular membranes in the choroid. Despite advancements with current anti-vascular endothelial growth factor (VEGF) therapies, challenges such as frequent injections, inadequate response, and patient-related concerns persist. Emerging therapeutics aim to reduce vision-loss through a variety of mechanisms. Gene therapies, including RGX-314 and Ixo-vec, express an anti-VEGF protein, and 4D-150, expresses an anti-VEGF protein and a VEGF-C inhibitory miRNA. Anti-VEGF associated therapeutics include OPT-302, targeting VEGF-C and VEGF-D, BI 836880, which inhibits VEGF-A and Ang-2 activity, and Tarcocimab tedromer, inhibiting all VEGF-A isoforms. Agents with novel mechanisms of action include UBX1325, which inhibits an anti-apoptotic protein, Restoret (EYE103), a Wnt agonist, and the tyrosine kinase inhibitors, EYP-1901, OTX-TKI, CLS-AX, and KHK4951.

194

项与 Surabgene Lomparvovec 相关的新闻（医药）

2026-01-20

·唐爱金团队研究

【信达医药】康弘药业(002773)公司首次覆盖报告：深耕眼科黄金赛道，基因治疗创新管线打开新空间

本文来自信达证券研发中心2026年1月19日发布的《康弘药业(002773)公司首次覆盖报告：深耕眼科黄金赛道，基因治疗创新管线打开新空间》，欲了解具体内容，请阅读报告原文，唐爱金S1500523080002。眼科创新药龙头，创新管线打开长期成长空间。康弘药业是国内眼科创新药领域的领军企业，产品布局覆盖眼科、精神/神经、消化、呼吸、高血压、糖尿病等治疗领域。公司目前上市在销的药品超过25个，其中11个为独家品种，20个品种纳入国家医保目录，10个品种纳入国家基药目录，核心产品康柏西普眼用注射液自2013年获批上市以来，已成功获批wAMD、pmCNV、DME、RVO四大眼底疾病适应症。公司累计有13项研发管线处于临床阶段，进度较快的管线包括KH110（III期）、KH109（III期）、KH631（II期）。财务表现稳健，2025Q1-3公司实现营业收入36.24亿元，同比增长6.23%，实现归母净利润10.33亿元，同比增长6.08%，综合毛利率维持在90%左右，费用端控制良好，净利率稳步提升至29%。千亿眼科疾病蓝海市场，康柏西普高速增长。眼底疾病是一类复杂程度高、难治愈且患者视力预后较差的眼科疾病，目前该领域治疗手段有限，仍存在大量未满足的临床需求。2030年全球眼科药物市场规模有望突破700亿美元，抗VEGF药物为主流治疗手段，国内市场规模有望超200亿元。国内已上市眼科抗VEGF药物包括5款原研药及2款生物类似药，康柏西普上市十余年销售持续增长，累计实现销售额130亿元，2025H1市场份额约40.55%，位列第一。当前康柏西普渗透率仅为0.6%，存在渗透率提升空间，考虑到医保覆盖持续深化及基层市场不断拓展，我们认为康柏西普可持续为公司提供业绩支撑。眼科基因治疗行业迎窗口期，全球竞速步入白热化下半场。眼科基因治疗正凭借“单次治疗、长期获益”等优势颠覆传统疗法。截止2025年10月，全球共有超过90款临床在研眼科基因疗法，已上市药物仅1款，NDA阶段2款，临床III期阶段11款。抗VEGF基因治疗产品RGX-314进度最快，已进展至临床III期，其疗效在多项II期临床试验中得到验证。创新管线梯队渐成，基因治疗国内进度领先。公司在眼科基因治疗领域前瞻性布局，KH631已进入临床II期，KH658处于临床I期，研发进度国内领先。两款产品均采用AAV载体递送抗VEGF基因，通过在视网膜细胞内持续表达抗VEGF蛋白，使患者实现一次治疗、长期获益。其余研发管线储备丰富，临床III期管线包括KH110（阿尔茨海默症）、KH109（焦虑症）；临床II期管线包括KH617（实体瘤）、KH607（抑郁症）、高剂量康柏西普KH902-R10（DME）；临床I期管线包括双载荷ADC药物KH815（实体瘤）、Nav1.8抑制剂KHN702（急性疼痛）等，多个品种具备成为重磅产品的潜力。盈利预测与投资评级我们预计2025-2027年公司营业收入分别为48.89亿元、51.26亿元、54.18亿元，归母净利润分别为12.54亿元、13.37亿元、14.31亿元，对应的EPS分别为1.36、1.45元、1.55元，对应的PE估值分别为24.84倍、23.31倍、21.78倍（截至2026年1月19日）。首次覆盖，给予“买入”评级。风险因素核心产品竞争加剧与降价风险；创新药研发失败风险；政策与市场环境变化风险；高管及核心技术人员流失风险。

临床3期基因疗法财报上市批准生物类似药

2026-01-19

·同花顺

信达证券：首次覆盖康弘药业给予买入评级

信达证券（601059）股份有限公司唐爱金近期对康弘药业（002773）进行研究并发布了研究报告《公司首次覆盖报告：深耕眼科黄金赛道，基因治疗创新管线打开新空间》，首次覆盖康弘药业给予买入评级。康弘药业眼科创新药龙头，创新管线打开长期成长空间康弘药业是国内眼科创新药领域的领军企业，产品布局覆盖眼科、精神/神经、消化、呼吸、高血压、糖尿病等治疗领域。公司目前上市在销的药品超过25个，其中11个为独家品种，20个品种纳入国家医保目录，10个品种纳入国家基药目录，核心产品康柏西普眼用注射液自2013年获批上市以来，已成功获批wAMD、pmCNV、DME、RVO四大眼底疾病适应症。公司累计有13项研发管线处于临床阶段，进度较快的管线包括KH110(III期)、KH109(III期)、KH631(II期)。财务表现稳健，2025Q1-3公司实现营业收入36.24亿元，同比增长6.23%，实现归母净利润10.33亿元，同比增长6.08%，综合毛利率维持在90%左右，费用端控制良好，净利率稳步提升至29%。千亿眼科疾病蓝海市场，康柏西普高速增长眼底疾病是一类复杂程度高、难治愈且患者视力预后较差的眼科疾病，目前该领域治疗手段有限，仍存在大量未满足的临床需求。2030年全球眼科药物市场规模有望突破700亿美元，抗VEGF药物为主流治疗手段，国内市场规模有望超200亿元。国内已上市眼科抗VEGF药物包括5款原研药及2款生物类似药，康柏西普上市十余年销售持续增长，累计实现销售额130亿元，2025H1市场份额约40.55%，位列第一。当前康柏西普渗透率仅为0.6%，存在渗透率提升空间，考虑到医保覆盖持续深化及基层市场不断拓展，我们认为康柏西普可持续为公司提供业绩支撑。眼科基因治疗行业迎窗口期，全球竞速步入白热化下半场眼科基因治疗正凭借“单次治疗、长期获益”等优势颠覆传统疗法。截止2025年10月，全球共有超过90款临床在研眼科基因疗法，已上市药物仅1款，NDA阶段2款，临床III期阶段11款。抗VEGF基因治疗产品RGX-314进度最快，已进展至临床III期，其疗效在多项II期临床试验中得到验证。创新管线梯队渐成，基因治疗国内进度领先公司在眼科基因治疗领域前瞻性布局，KH631已进入临床II期，KH658处于临床I期，研发进度国内领先。两款产品均采用AAV载体递送抗VEGF基因，通过在视网膜细胞内持续表达抗VEGF蛋白，使患者实现一次治疗、长期获益。其余研发管线储备丰富，临床III期管线包括KH110(阿尔茨海默症)、KH109(焦虑症)；临床II期管线包括KH617(实体瘤)、KH607(抑郁症)、高剂量康柏西普KH902-R10(DME)；临床I期管线包括双载荷ADC药物KH815(实体瘤)、Nav1.8抑制剂KHN702(急性疼痛)等，多个品种具备成为重磅产品的潜力。盈利预测与投资评级：我们预计2025-2027年公司营业收入分别为48.89亿元、51.26亿元、54.18亿元，归母净利润分别为12.54亿元、13.37亿元、14.31亿元，对应的EPS分别为1.36、1.45元、1.55元，对应的PE估值分别为24.84倍、23.31倍、21.78倍(截至2026年1月19日)。首次覆盖，给予“买入”评级。风险因素：核心产品竞争加剧与降价风险；创新药研发失败风险；政策与市场环境变化风险；高管及核心技术人员流失风险。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，买入评级1家。

2026-01-19

·证券之星

公司首次覆盖报告：深耕眼科黄金赛道，基因治疗创新管线打开新空间

（以下内容从信达证券《公司首次覆盖报告：深耕眼科黄金赛道，基因治疗创新管线打开新空间》研报附件原文摘录）康弘药业(002773)眼科创新药龙头，创新管线打开长期成长空间康弘药业是国内眼科创新药领域的领军企业，产品布局覆盖眼科、精神/神经、消化、呼吸、高血压、糖尿病等治疗领域。公司目前上市在销的药品超过25个，其中11个为独家品种，20个品种纳入国家医保目录，10个品种纳入国家基药目录，核心产品康柏西普眼用注射液自2013年获批上市以来，已成功获批wAMD、pmCNV、DME、RVO四大眼底疾病适应症。公司累计有13项研发管线处于临床阶段，进度较快的管线包括KH110（III期）、KH109（III期）、KH631（II期）。财务表现稳健，2025Q1-3公司实现营业收入36.24亿元，同比增长6.23%，实现归母净利润10.33亿元，同比增长6.08%，综合毛利率维持在90%左右，费用端控制良好，净利率稳步提升至29%。千亿眼科疾病蓝海市场，康柏西普高速增长眼底疾病是一类复杂程度高、难治愈且患者视力预后较差的眼科疾病，目前该领域治疗手段有限，仍存在大量未满足的临床需求。2030年全球眼科药物市场规模有望突破700亿美元，抗VEGF药物为主流治疗手段，国内市场规模有望超200亿元。国内已上市眼科抗VEGF药物包括5款原研药及2款生物类似药，康柏西普上市十余年销售持续增长，累计实现销售额130亿元，2025H1市场份额约40.55%，位列第一。当前康柏西普渗透率仅为0.6%，存在渗透率提升空间，考虑到医保覆盖持续深化及基层市场不断拓展，我们认为康柏西普可持续为公司提供业绩支撑。眼科基因治疗行业迎窗口期，全球竞速步入白热化下半场眼科基因治疗正凭借“单次治疗、长期获益”等优势颠覆传统疗法。截止2025年10月，全球共有超过90款临床在研眼科基因疗法，已上市药物仅1款，NDA阶段2款，临床III期阶段11款。抗VEGF基因治疗产品RGX-314进度最快，已进展至临床III期，其疗效在多项II期临床试验中得到验证。创新管线梯队渐成，基因治疗国内进度领先公司在眼科基因治疗领域前瞻性布局，KH631已进入临床II期，KH658处于临床I期，研发进度国内领先。两款产品均采用AAV载体递送抗VEGF基因，通过在视网膜细胞内持续表达抗VEGF蛋白，使患者实现一次治疗、长期获益。其余研发管线储备丰富，临床III期管线包括KH110（阿尔茨海默症）、KH109（焦虑症）；临床II期管线包括KH617（实体瘤）、KH607（抑郁症）、高剂量康柏西普KH902-R10（DME）；临床I期管线包括双载荷ADC药物KH815（实体瘤）、Nav1.8抑制剂KHN702（急性疼痛）等，多个品种具备成为重磅产品的潜力。盈利预测与投资评级：我们预计2025-2027年公司营业收入分别为48.89亿元、51.26亿元、54.18亿元，归母净利润分别为12.54亿元、13.37亿元、14.31亿元，对应的EPS分别为1.36、1.45元、1.55元，对应的PE估值分别为24.84倍、23.31倍、21.78倍（截至2026年1月19日）。首次覆盖，给予“买入”评级。风险因素：核心产品竞争加剧与降价风险；创新药研发失败风险；政策与市场环境变化风险；高管及核心技术人员流失风险。

100 项与 Surabgene Lomparvovec 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脉络膜新生血管	临床3期	美国	AbbVie, Inc.	2022-01-13
脉络膜新生血管	临床3期	日本	AbbVie, Inc.	2022-01-13
脉络膜新生血管	临床3期	加拿大	AbbVie, Inc.	2022-01-13
脉络膜新生血管	临床3期	法国	AbbVie, Inc.	2022-01-13
脉络膜新生血管	临床3期	德国	AbbVie, Inc.	2022-01-13
脉络膜新生血管	临床3期	匈牙利	AbbVie, Inc.	2022-01-13
脉络膜新生血管	临床3期	意大利	AbbVie, Inc.	2022-01-13
脉络膜新生血管	临床3期	西班牙	AbbVie, Inc.	2022-01-13
脉络膜新生血管	临床3期	英国	AbbVie, Inc.	2022-01-13
II型糖原贮积病	临床3期	美国	AbbVie, Inc.	2022-01-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EURETINA2025	临床1/2期	湿性年龄相关性黄斑变性	10	ABBV-RGX-314 (bilateral choroidal neovascularization secondary to age-related macular degeneration)	憲廠衊窪鬱膚顧築遞鹽(範積淵淵觸鏇鹹艱壓蓋) = 衊觸壓衊糧網獵鹽觸廠簾構觸襯襯鏇製範廠選 (糧衊淵窪艱艱餘鑰顧鑰 ) 更多	积极	2025-09-04
NCT04514653 (AAVIATE, Corporate Publications) 人工标引	临床2期	湿性黄斑变性	106	ABBV-RGX-314	衊廠鏇壓鹹艱齋憲鹹醖(蓋鹽鬱鬱積製選網獵襯) = in the study eye were mild or moderate and included conjunctival hemorrhage, increased intraocular pressure, episcleritis, and conjunctival hyperemia. 網蓋觸窪繭鏇鹽積淵網 (夢鹹網積糧繭餘艱顧餘 ) 更多	积极	2024-01-16
EURETINA2023	N/A	糖尿病性黄斑水肿	-	RGX-314 at a dose level of 2.5 x E11 GC/eye	製夢襯築範餘鹹鹽淵鑰(醖簾積範餘積顧鑰鹽艱) = three cases of mild intraocular inflammation through 6 months which resolved with topical corticosteroids 範鏇淵製壓鏇繭淵製簾 (糧憲鹽鏇餘憲鏇壓選鹹 ) 更多	-	2023-10-05
EURETINA2023	N/A	糖尿病性黄斑水肿	-	RGX-314 at an increased dose level of 5 x E11 GC/eye		-	2023-10-05
EURETINA2023	N/A	年龄相关性黄斑变性	-	RGX-314	衊獵構範製齋網築糧窪(襯糧觸築遞鏇獵糧選製) = No new drug-related ocular adverse events (AEs) have been reported in Cohorts 1-4 遞鹹觸選願壓簾獵繭襯 (醖積願遞膚選膚顧構蓋 ) 更多	-	2023-10-05
Phase I/IIa (ARVO2023)	临床1/2期	湿性年龄相关性黄斑变性	42	RGX-314	鹽憲簾鹹齋襯膚簾構憲(構艱壓鏇廠憲繭簾鏇鏇) = no new drug-related ocular adverse events reported in Cohorts 1-4 and one drug-related adverse event of significantly decreased BCVA in Cohort 5 艱蓋簾網鹽構鹹繭糧鹽 (衊簾齋蓋製蓋製繭獵範 )	积极	2023-04-23
NCT04567550 (ALTITUDE, Corporate Publications) 人工标引	临床2期	糖尿病性视网膜病变	60	RGX-314	繭鹽醖獵鏇蓋獵膚築鹹(製艱齋遞壓遞鬱壓範顧) = 糧壓襯壓鹹選獵範糧糧築觸觸顧餘蓋鑰膚製廠 (簾網淵艱艱鹹簾鬱醖鑰 ) 更多	积极	2022-11-02
NCT04567550 (ALTITUDE, Corporate Publications) 人工标引	临床2期	糖尿病性视网膜病变	60	control	繭鹽醖獵鏇蓋獵膚築鹹(製艱齋遞壓遞鬱壓範顧) = 淵淵網繭遞襯鏇窪廠範築觸觸顧餘蓋鑰膚製廠 (簾網淵艱艱鹹簾鬱醖鑰 ) 更多	积极	2022-11-02
NCT04567550 (ALTITUDE, Corporate Publications) 人工标引	临床2期	糖尿病性视网膜病变	20	RGX-314	淵網鹽簾範願觸淵簾繭(窪夢構觸顧膚鏇糧襯獵) = 憲築構築觸積願鏇憲鬱鹽壓膚窪鬱壓衊膚築鏇 (膚範範構選膚糧壓獵壓 ) 更多	积极	2022-09-13
NCT04567550 (ALTITUDE, Corporate Publications) 人工标引	临床2期	糖尿病性视网膜病变	20	Observational	淵網鹽簾範願觸淵簾繭(窪夢構觸顧膚鏇糧襯獵) = 範積願壓遞網繭獵選製鹽壓膚窪鬱壓衊膚築鏇 (膚範範構選膚糧壓獵壓 ) 更多	积极	2022-09-13
NCT04514653 (AAVIATE, PRNewswire) 人工标引	临床2期	湿性年龄相关性黄斑变性	19	RGX-314	積範醖齋範廠願齋鏇獵(齋築積構壓網夢鏇簾築) = 構顧齋鏇憲鬱製餘築顧壓範築築獵簾繭顧觸觸 (築觸築選壓壓壓範艱鹽 ) 更多	积极	2021-10-01
NCT04514653 (AAVIATE, PRNewswire) 人工标引	临床2期	湿性年龄相关性黄斑变性	19	Ranibizumab	積範醖齋範廠願齋鏇獵(齋築積構壓網夢鏇簾築) = 蓋簾鏇艱齋壓製鹽鏇衊壓範築築獵簾繭顧觸觸 (築觸築選壓壓壓範艱鹽 ) 更多	积极	2021-10-01
EURETINA2021	N/A	湿性年龄相关性黄斑变性	-	RGX-314	觸憲窪觸糧鹽積窪蓋築(範鑰鑰膚獵繭積壓簾淵) = 20 serious adverse events (SAEs) reported in 13 patients, including one possibly drug-related SAE of significant decrease in vision in Cohort 5 衊鹽獵製膚糧鑰網憲鏇 (範繭憲選夢膚網鬱鑰選 ) 更多	-	2021-09-01
RGX-314 (ASGCT2020)	临床1/2期	湿性年龄相关性黄斑变性	42	RGX-314 gene therapy	遞顧觸範範艱構構夢選(憲獵憲壓繭艱壓觸網醖) = improved central retinal thickness (-83 µm) 製憲顧構鹽範鏇鹹範鹹 (遞醖鏇蓋廠積夢構製窪 ) 更多	积极	2020-04-28